# Ipamorelin Research: Mechanism, Key Studies & the Evidence > Ipamorelin research summarized: GHS-R1a mechanism, the founding selectivity study, human pharmacokinetics, the failed Phase 2 trial, and bone-growth data. Every figure cited. The mechanism, the studies that define the record, and the comparisons readers ask for — sorted and cited. ## Start here Ipamorelin research is easier to follow if you hold one idea first: this is a peptide that makes the pituitary release a single, clean pulse of growth hormone, and almost everything else follows from that. It does this by switching on the ghrelin receptor (GHS-R1a) — the same receptor the natural hunger hormone uses — on the growth-hormone cells of the pituitary [1]. The landmark finding, from 1998, is that it does so *selectively*: a strong GH pulse with no meaningful rise in stress hormones [1]. From there the research splits into a few threads — how long it lasts in the body, what it does to bone, what it does under metabolic stress, and how it pairs with other peptides. The catch, repeated below, is that the deep data is in animals; the human record is two small studies and one trial that failed [2][3]. ## Mechanism: a selective ghrelin-receptor switch Ipamorelin binds the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs — the GH-producing cells — and triggers GH release through the Gq/PLC pathway, which raises intracellular calcium [1]. It releases GH by a route distinct from GHRH (growth-hormone-releasing hormone), the body's other GH trigger, which is exactly why it is paired with GHRH analogs: the two pathways are complementary, not redundant. Downstream, GH can raise hepatic IGF-1, though notably this was *not* consistently elevated in short rodent studies — in the rat bone-growth work, IGF-1 did not move even as bone growth did [4]. The receptor also sits on enteric neurons (the basis for the gut-motility program ipamorelin was trialled for) and on pancreatic islet cells. ## The founding study: selectivity, defined The 1998 characterisation by Raun and colleagues is the study every later claim leans on [1]. Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) released GH potently in three systems: primary rat pituitary cells, anaesthetised rats, and conscious swine. In pigs its potency (ED50 = 2.3 ± 0.03 nmol/kg) was comparable to the older peptide GHRP-6 (3.9 nmol/kg). The decisive result was what it did *not* do: even at doses more than 200-fold above its GH-releasing dose, it did not raise ACTH or cortisol above the level seen with GHRH alone. That made it the first highly GH-selective growth hormone secretagogue — the property that distinguishes it from GHRP-6 and GHRP-2 to this day. The characterisation was acute, not chronic, which is worth holding onto. ## Human pharmacokinetics: the one clean human dataset Ipamorelin's behaviour in people was mapped once, well, in 1999 [2]. In healthy male volunteers (eight per dose level) given five 15-minute IV infusions ranging from 4.21 to 140.45 nmol/kg, the kinetics were dose-proportional: a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg. The GH response was a single discrete pulse peaking at roughly 0.67 hours — about 40 minutes — after dosing. This is one of the only human ipamorelin datasets in existence, and it describes pharmacology, not outcomes: it tells you how the molecule moves and how the GH pulse rises and falls, not whether anything therapeutic results. ## The bone-growth signal: a dose-response without IGF-1 The clearest body-composition-adjacent finding comes from adult female Sprague-Dawley rats [4]. Subcutaneous ipamorelin at 18, 90, and 450 µg/day — divided three times daily for 15 days — raised the longitudinal bone growth rate from 42 µm/day on vehicle to 44, 50, and 52 µm/day respectively, a clean dose-dependent climb. What makes it interesting is the absence: total IGF-1, the IGF binding proteins, and bone-turnover markers did not change. That points to a partly local, GH-pulse-driven skeletal effect rather than one mediated by a sustained systemic IGF-1 rise — and it is a useful caution against assuming ipamorelin's effects always run through IGF-1. ## The most recent in-vivo finding: weight defended, nausea unchanged The freshest published in-vivo ipamorelin study, from 2024, used a ferret model of chemotherapy toxicity [5]. Intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase (48–72 hours). It had no anti-emetic effect on either acute or delayed emesis — in contrast to a centrally-administered comparator, which cut acute emesis by 60%. The reading: ipamorelin defended body weight through a peripheral mechanism without touching nausea, which is both the most recent and one of the most directly body-composition-relevant findings in the record. ## The human efficacy anchor: a trial that missed The single most important human study is also a negative one [3]. The only published Phase 2 RCT (NCT00672074) gave 0.03 mg/kg IV twice daily, for up to seven days, to 114 adults undergoing bowel resection, testing ipamorelin for postoperative ileus. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p = 0.15) — a numerical difference that did not reach significance. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo, showing no ipamorelin-specific safety signal in that short window. Efficacy, for the one indication taken into a controlled human trial, was not demonstrated. ## What is ipamorelin peptide What is ipamorelin peptide, in one paragraph: it is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — derived from the earlier peptide GHRP-1 by removing a central dipeptide [1]. The non-natural building blocks (alpha-aminoisobutyric acid at position one; D-form naphthylalanine and phenylalanine) make it resist the enzymes that would otherwise break it down. It is not an endogenous human peptide; it mimics the action of ghrelin at the GHS-R1a receptor. Molecular formula C38H49N9O5, molecular weight about 711.9 Da, CAS 170851-70-4. Functionally, it is the prototype of the *selective* growth hormone secretagogue. ## What is cjc-1295 ipamorelin What is cjc-1295 ipamorelin: it is the popular pairing of ipamorelin with CJC-1295, a long-acting GHRH analog. The rationale is mechanistic complementarity — CJC-1295 works through the GHRH receptor (a cAMP pathway), ipamorelin through the ghrelin receptor (a calcium pathway), so co-administration engages both GH-release routes at once [1]. It is widely promoted as a body-composition and recovery 'stack.' The evidence caveat is firm: the combination is supported by the separate single-agent pharmacology of each peptide, not by any controlled trial of the pair for any outcome. No combination trial exists. ## Ipamorelin cjc-1295 Ipamorelin cjc-1295 protocols dominate community use, which is why the question recurs. Pharmacologically the pairing is rational: ipamorelin contributes a clean, selective GH pulse with minimal cortisol or prolactin involvement [1], while CJC-1295 extends GHRH-side stimulation. But the combination has never been tested as a unit in a controlled human study, and ipamorelin's own human record is limited to one pharmacokinetic study [2] and one failed efficacy trial [3]. Any account of the 'stack' therefore describes two separately-characterised peptides administered together, not a validated combination therapy — an important distinction the marketing tends to blur. ## Ipamorelin vs sermorelin Ipamorelin vs sermorelin is a comparison of two different mechanisms, not two versions of one thing. Sermorelin is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist acting through a separate pathway [1]. Because they hit complementary receptors, they are sometimes combined rather than chosen between. The cleanest factual contrast: sermorelin once had an approved formulation in the United States that was later withdrawn from the market, whereas ipamorelin was never approved anywhere and its one Phase 2 efficacy trial failed [3]. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin contrasts an unapproved ghrelin-receptor agonist with an actually-approved GHRH analog. Tesamorelin is a stabilised GHRH analog with an approved indication (reduction of excess visceral fat in HIV-associated lipodystrophy) and real human outcome data behind it. Ipamorelin acts through the different ghrelin/GHS-R1a pathway [1], has no approved indication anywhere, and its only controlled human efficacy trial — for postoperative ileus — missed its endpoint [3]. The practical takeaway is the asymmetry in evidence: one has approved human outcomes for a defined use; the other has mechanism, animal data, and an unmet human bar. ## Is ipamorelin fda approved Is ipamorelin fda approved — no. Ipamorelin has never been approved by the FDA (or any regulatory authority) as a drug for any indication [3]. It was investigated for postoperative ileus but never approved. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list following nominator withdrawal, and reviewed ipamorelin acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting; it is not an approved bulk substance for compounding. It is marketed only as a research chemical, and is prohibited in sport at all times under WADA category S2. --- A body-composition reading of the ipamorelin record set in aubergine and a single pulse of citation-blue — the clean selective GH-pulse finding raised first, the bone-growth and weight-defence animal data kept to their own studies, and the failed human trial and the missing long-term safety left openly unlit; no clinic behind the plum and nothing here dosed, compounded, prescribed, or sold.